Inspra Helps, Natrecor Useless for Heart Patients
By wchung | 08 Jul, 2026
There’s good news for millions of people with mild or moderate heart failure. Studies show that the Pfizer drug Inspra and an implanted device from Medtronic can boost survival and cut down on trips to the hospital.
However, another drug that has been used for nearly a decade, Johnson & Johnson’s Natrecor (NAY’-treh-kor), did little to help people with severe heart failure in a study aimed at resolving safety concerns. Doctors say the drug seems safe but does not markedly help shortness of breath or save lives.
The studies were presented Sunday at an American Heart Association conference in Chicago.
MARILYNN MARCHIONE, AP Medical Writer CHICAGO
© 2026 by Asian Media Group Inc.
Recent Articles
- China Becomes Innovation Engine for Top Global Legacy Carmakers
- Big Tech Data Centers Drive Up Power Bills at America's Rust Belt Factories
- AstraZeneca Pays $200 Mil. Upfront to License Chinese COPD Drug
- Korean Chip Stocks Rebound from Overnight US Selloff as Chip Supply Remains Tight
- DeepSeek Developing AI Chip in Possible Setback for Majors
- Eala and Osaka’s Wimbledon Upsets, Sudo Retains Belt, MLB All-Star Watch
- China Gold Reserves Rise Most Since 2023 As Bullion Tumbles
- Italy's Meloni Seeks to Avoid Escalation After Trump Revives Personal Feud
- Canada's May Trade Surplus Surged to 4-Year High on US Exports
- Beijing Mulls Curbing Overseas Access to China's Top AI Models
